



X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March

February 25, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2020--

[X4 Pharmaceuticals, Inc.](#) (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team will present and conduct one-on-one meetings at Cowen and Company's 40th Annual Health Care Conference and Oppenheimer's 30th Annual Healthcare Conference.

Details are as follows:

Conference: Cowen and Company's 40th Annual Health Care Conference

Location: Boston Marriott Copley Place, Boston, MA

Date: Monday, March 2, 2020

Time: 3:30 PM ET

Conference: Oppenheimer's 30th Annual Healthcare Conference

Location: InterContinental New York Barclay, New York, NY

Date: Wednesday, March 18, 2020

Time: 2:45 PM ET

A live webcast of the presentation from Cowen and Company's 40th Annual Health Care Conference will be available on the investors section of the X4 Pharmaceuticals' website at www.x4pharma.com. After the live webcast, the event will remain archived on the X4 Pharmaceuticals' website for approximately 90 days.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company's oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC), with several patients remaining on therapy over 12 months beyond the primary endpoint. X4 is further investigating mavorixafor in a Phase 1b clinical trial for the treatment of Severe Congenital Neutropenia (SCN), and with ibrutinib for the treatment of Waldenström's macroglobulinemia (WM). X4 was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit www.x4pharma.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200225005174/en/): <https://www.businesswire.com/news/home/20200225005174/en/>

Investors and Media:

Candice Ellis, 857-341-1043

Director, Corporate Communications & Investor Relations

Candice.Ellis@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

Investors and Media:

Candice Ellis, 857-341-1043

Director, Corporate Communications & Investor Relations

Candice.Ellis@x4pharma.com